


<!DOCTYPE html>
<html lang="en">
<head>  

        <title>Screening for Cognitive Impairment in Older Adults | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//www.googletagmanager.com/ns.html?id=GTM-W4NX5V"
                height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//www.googletagmanager.com/ns.html?id=GTM-KHDP6Z"
                height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/" class="header-logo NGC">
				    <picture>
				        <source
				            media="(min-width: 960px)"
				            srcset="/UI/images/logo_NGC_header.png">
				        <source
				            srcset="/UI/images/logo_NGC_header_m.png">
				        <img
				            src="/UI/images/logo_NGC_header.png"
				            alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In" />
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/">Home</a></li>
		        <li class=""><a href="/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/browse/organization">By Organization</a></li>
		                <li class=""><a href="/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/summaries/archive">Archive</a></li>

		                <li class=""><a href="/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class='content'><div class='fundingNotice2'><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href='/home/announcements'>full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

	<!-- CONTENT HEADER -->
	<div class="content-header">
		<ul class="content-header-meta">
			<li class="prefix-icon large-icon synthesis">Guideline Synthesis</li>
		</ul>
		<h1>Screening for Cognitive Impairment in Older Adults</h1>
	</div><!-- /.content-header -->

	<!-- COMPARED LIST-->
		<p>Guidelines Being Compared:</p>
		<ul class="compared-list"> 
				<li>
                    <p class="compared-list-org">Canadian Task Force on Preventive Health Care (CTFPHC)</p>
					<p class="compared-list-title">Recommendations on screening for cognitive impairment in older adults.</p>
                    <p class="compared-list-org">2016 Jan 05</p>
					<p><a class="prefix-icon guideline" href="/summaries/summary/49951">View Summary</a></p>					
				</li>
				<li>
                    <p class="compared-list-org">U.S. Preventive Services Task Force (USPSTF)</p>
					<p class="compared-list-title">Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement.</p>
                    <p class="compared-list-org">2014 Jun 03</p>
					<p><a class="prefix-icon guideline" href="/summaries/summary/48059">View Summary</a></p>					
				</li>
		</ul><!-- /.compared-list -->
			
	<!-- TOOLBAR -->
	<div class="content-toolbar">
		<!-- Primary -->
		<ul class="tools primary-tools">
			<li class="dropdown tool sections">
				<a href="#" class="tool-button">Sections</a>
				<div class="dropdown-panel">
						<ul class="section-links">
								<li><a href="#504" class="section-mark">Areas of Agreement and Difference</a></li>
								<li><a href="#505" class="section-mark">Comparison of Recommendations</a></li>
								<li><a href="#506" class="section-mark">Strength of Evidence and Recommendation Grading Schemes</a></li>
								<li><a href="#507" class="section-mark">Methodology</a></li>
								<li><a href="#509" class="section-mark">Benefits and Harms</a></li>
								<li><a href="#511" class="section-mark">Abbreviations</a></li>
								<li><a href="#512" class="section-mark">Status</a></li>
						</ul>    
				</div><!-- /.dropdown-panel -->
			</li>
		</ul><!-- /.tools primary-tools -->

		<!-- Other -->
		<ul class="tools other-tools">
			<li class="dropdown tool">
				<a href="#" class="tool-button">Share</a>
				<div class="dropdown-panel">
					<ul class="toolbar-social">
						<li><a target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/syntheses/synthesis/50671" class="facebook">Facebook</a></li>
						<li><a target="_blank" href="https://twitter.com/share?text=&url=https://www.guideline.gov/syntheses/synthesis/50671" class="twitter">Twitter</a></li>
						<li><a target="_blank" href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.guideline.gov/syntheses/synthesis/50671&title=&summary=&source="  class="linkedin">Linkedin</a></li>
						<li><a href="mailto:?Subject=AHRQ: Screening for Cognitive Impairment in Older Adults&body=https://www.guideline.gov/syntheses/synthesis/50671" class="email">Email</a></li>
					</ul><!-- /.toolbar-social -->
				</div><!-- /.dropdown-panel -->
			</li>
			<li class="dropdown tool">
				<a href="#" class="tool-button">Cite</a>
				<div class="dropdown-panel citation">
				    <p class="text-label"><label for="citation">Citation: </label></p>
					<textarea id="citation">Internet citation: National Guideline Clearinghouse (NGC). Guideline synthesis: Screening for cognitive impairment in older adults. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2017 May. [cited YYYY Mon DD]. Available: http://www.guideline.gov.</textarea>
				</div><!-- /.dropdown-panel -->
			</li>
		</ul><!-- /.tools other-tools -->

		<!-- Accordion tools -->
		<ul class="tools accordion-controls">
			<li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
			<li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
		</ul><!-- /.accordion-controls -->
	</div><!-- /.toolbar -->            

		<!-- ARTICLE -->
		<div class="article" id="article">
			



	<!-- ACCORDION -->
	<div class="accordion-container" role="tablist" multiselectable="true">
			<h2 class="accordion-title is-active" id="504" role="tab" aria-expanded="true" aria-controls="syn504"><a href="#">Areas of Agreement and Difference</a></h2>
			<div class="accordion-panel is-active" id="syn504" role="tabpanel" aria-labelledby="504" ><a name="areasofagreementanddifference"></a>
<p>A direct comparison of recommendations presented in the above guidelines for screening for cognitive impairment in adults is provided. The recommendations address screening community-dwelling adults 65 years of age or older without symptoms suggestive of cognitive impairment or dementia using formal screening instruments (e.g., the MMSE).</p>
<h3><a name="agreement"></a>Areas of Agreement</h3>
<p>Neither guideline developer recommends routine screening for cognitive impairment in asymptomatic adults aged 65 or older. See <strong>Areas of Difference</strong> below for information.</p>
<h3><a name="difference"></a>Areas of Difference</h3>
<h4>Screening for Cognitive Impairment in Older Adults</h4>
<p>The guideline developers offer different guidance for screening asymptomatic, community-dwelling adults 65 years of age or older for cognitive impairment using formal screening instruments (e.g., the MMSE). The USPSTF concluded that the evidence on screening for cognitive impairment in this population is lacking and that the balance of benefits and harms cannot be determined (an "<strong>I statement</strong>"). Although the overall evidence on routine screening is insufficient, the USPSTF provides suggestions for implementing the I statement in clinical practice. The developer recommends that clinicians remain alert to early signs or symptoms of cognitive impairment (for example, problems with memory or language) and evaluate as appropriate. Recognizing early cognitive impairment can help patients make diagnostic and treatment decisions, and allows clinicians to anticipate problems patients may have in understanding and adhering to recommended therapy, notes the USPSTF. This information may also be useful to patients and their caregivers and family members in anticipating and planning for future problems that may develop as a result of progression of cognitive impairment.</p>
<p>On the basis of low-quality evidence, CTFPHC strongly <em>recommends against</em> screening asymptomatic adults 65 years of age or older for cognitive impairment. Given the lack of evidence on the efficacy of screening and the lack of clinically effective treatments for MCI, the CTFPHC felt a strong recommendation against screening asymptomatic patients for cognitive impairment was warranted. The developer explains that this recommendation places a relatively higher value on the lack of evidence evaluating the benefits and harms of screening, evidence showing that pharmacologic treatment is not effective, and evidence showing a small but clinically insignificant benefit of nonpharmacologic treatment. A relatively lower value is placed on limited evidence about patient preferences and limited evidence showing that treatment of MCI is not associated with an increase of serious adverse events or psychosocial harms. Although CTFPHC recommends against screening for cognitive impairment, it also provides considerations for implementation of this recommendation. Similar to USPSTF, CTFPHC encourages practitioners to examine and assess cognitive functions and functional autonomy whenever a patient presents with signs and symptoms of impairment, or when family members or patients express concerns about potential cognitive decline. </p></div>
			<h2 class="accordion-title is-active" id="505" role="tab" aria-expanded="true" aria-controls="syn505"><a href="#">Comparison of Recommendations</a></h2>
			<div class="accordion-panel is-active" id="syn505" role="tabpanel" aria-labelledby="505" ><p><h3>Screening for Cognitive Impairment in Older Adults</h3>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="Table: Provides a comparison of recommendations considered by each group">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top" headers="screening">CTFPHC<br />
            (2016)</th>
            <td valign="top" style="width: 90%;" headers="screening">
            <p><strong><span style="text-decoration: underline;">Summary of Recommendations for Clinicians and Policy-makers</span></strong></p>
            <p>The CTFPHC recommends not screening asymptomatic adults 65 years of age or older for cognitive impairment. (<strong>Strong recommendation, low quality evidence</strong>)</p>
            <p>The recommendation applies to community-dwelling adults 65 years of age or older in whom cognitive impairment has not been identified as a specific concern. This recommendation does not apply to men and women who have symptoms suggestive of cognitive impairment (e.g., loss of memory, language, attention, visuospatial or executive functioning, or behavioural or psychological symptoms) or who are suspected of having cognitive impairment by clinicians, family or friends.</p>
            <p><strong>Rationale for Recommendation</strong></p>
            <p>The findings of the evidence review highlight the lack of high-quality studies evaluating the benefits and harms of screening for cognitive impairment and the lack of effective treatments for MCI. If screening for cognitive impairment were to be conducted in the asymptomatic general population, most cases detected would likely be MCI, not dementia. Therefore, the task force felt it was important to examine the effectiveness of treatments for MCI.</p>
            <p>Given the lack of evidence on the efficacy of screening for cognitive impairment and the lack of clinically effective treatments for MCI, the task force felt a strong recommendation against screening asymptomatic patients for cognitive impairment was warranted. A strong recommendation means that the task force is confident that the benefits do not outweigh the risks of screening most asymptomatic individuals 65 years of age and older.</p>
            <p>This recommendation places a relatively higher value on the lack of evidence evaluating the benefits and harms of screening, evidence showing that pharmacologic treatment is not effective, and evidence showing a small benefit of nonpharmacologic treatment, which was not clinically significant. This recommendation places a relatively lower value on limited evidence about patient preferences, which showed that about 50% of first-degree relatives of people with diagnosed cognitive impairment may be willing to be screened (see "Patient values and preferences" in the original guideline document), and limited evidence showing that treatment of MCI is not associated with an increase of serious adverse events or psychosocial harms.</p>
            <p>The evidence supporting this recommendation is rated overall as low quality because no evidence was found on the effectiveness of screening, because the RCTs evaluating the effectiveness of pharmacologic treatments were all rated as low quality, and because the five RCTs showing a small benefit (not clinically significant) of nonpharmacologic interventions on cognition, although rated as moderate quality, were downgraded because of serious study limitations.</p>
            </td>
        </tr>
        <tr>
            <th class="Center" valign="top" headers="screening">USPSTF<br />
            (2014)</th>
            <td valign="top" headers="screening">
            <p><strong><span style="text-decoration: underline;">Summary of Recommendation and Evidence</span></strong></p>
            <p>The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment. (<strong>I statement</strong>)</p>
            <p><strong><span style="text-decoration: underline;">Clinical Considerations</span></strong></p>
            <p><strong>Patient Population Under Consideration</strong></p>
            <p>This recommendation applies to universal screening with formal screening instruments in community-dwelling adults in the general primary care population who are older than age 65 years and have no signs or symptoms of cognitive impairment. Early detection and diagnosis of dementia through the assessment of patient-, family-, or physician-recognized signs and symptoms, some of which may be subtle, are not considered screening and are not the focus of this recommendation.</p>
            <p><strong>Suggestions for Practice Regarding the I Statement</strong></p>
            <p>Although the evidence on routine screening is insufficient, there may be important reasons to identify early cognitive impairment. In addition to its potential to help patients make diagnostic and treatment decisions, including treatment of reversible causes of dementia and management of comorbid conditions, early recognition of cognitive impairment allows clinicians to anticipate problems patients may have in understanding and adhering to recommended therapy. This information may also be useful to patients and their caregivers and family members in anticipating and planning for future problems that may develop as a result of progression of cognitive impairment. Although the overall evidence on routine screening is insufficient, clinicians should remain alert to early signs or symptoms of cognitive impairment (for example, problems with memory or language) and evaluate as appropriate. The National Institute on Aging has information on the detection and management of cognitive impairment for patients and clinicians, including a database of tools to detect cognitive impairment (available at <a href="https://www.nia.nih.gov/" target="_blank" title="National Institute on Aging Web site" >www.nia.nih.gov</a>&nbsp;<img alt="External Web Site Policy" src="/UI/images/icon_externallink.gif" />).</p>
            <p><strong>Screening Tests</strong></p>
            <p>Screening tests for cognitive impairment in the clinical setting generally include asking patients to perform a series of tasks that assess at least 1 cognitive domain (memory, attention, language, and visuospatial or executive functioning). Blood tests and radiology examinations are not currently used as screening tests but are often used after a positive screening result to confirm the diagnosis of dementia and determine its subtype. Although optimum sensitivity and specificity of the MMSE probably vary depending on the patient's age and education level, a large body of literature suggests that a general cut point of 23/24 or 24/25 (score considered "positive"/"negative") is appropriate for most primary care populations.</p>
            <p>Other instruments with more limited evidence include the Clock Drawing Test, Mini-Cog Test, Memory Impairment Screen, Abbreviated Mental Test, Short Portable Mental Status Questionnaire, Free and Cued Selective Reminding Test, 7-Minute Screen, Telephone Interview for Cognitive Status, and Informant Questionnaire on Cognitive Decline in the Elderly. Each of these tests has reasonable performance in some studies, but estimates of sensitivity and specificity vary, and the optimum diagnostic threshold or cut point for many of these instruments is unclear. For information on all instruments reviewed by the USPSTF, including the Montreal Cognitive Screening Assessment, the St. Louis University Mental Status examination, and other instruments with 2 or fewer studies, see the full evidence report (available from the <a href="/Home/Disclaimer?id=50671&contentType=synthesis&redirect=https%3a%2f%2fwww.uspreventiveservicestaskforce.org%2fPage%2fDocument%2fUpdateSummaryFinal%2fcognitive-impairment-in-older-adults-screening" title="USPSTF Web site">USPSTF Web site</a>&nbsp;<img alt="External Web Site Policy" src="/UI/images/icon_externallink.gif" /> [see also the "Availability of Companion Documents" field in the NGC summary]).</p>
            </td>
        </tr>
    </tbody>
</table></p></div>
			<h2 class="accordion-title is-active" id="506" role="tab" aria-expanded="true" aria-controls="syn506"><a href="#">Strength of Evidence and Recommendation Grading Schemes</a></h2>
			<div class="accordion-panel is-active" id="syn506" role="tabpanel" aria-labelledby="506" ><p><a name="strength"></a></p>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="This table presents the rating schemes used by the guideline groups to rate the level of evidence and/or the strength of the recommendations.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">CTFPHC<br />
            (2016)</th>
            <td valign="top" style="width: 90%;">
            <p><strong><span style="text-decoration: underline;">Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group Grades of Evidence</span></strong></p>
            <table role="presentation" border="1" cellspacing="1" cellpadding="3" summary="Table: Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group Grades of Evidence">
                <tbody>
                    <tr>
                        <td valign="top"><strong>High quality</strong> &mdash; Further research is very unlikely to change confidence in the estimate of effect.</td>
                    </tr>
                    <tr>
                        <td valign="top"><strong>Moderate quality</strong> &mdash; Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.</td>
                    </tr>
                    <tr>
                        <td valign="top"><strong>Low quality</strong> &mdash; Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.</td>
                    </tr>
                    <tr>
                        <td valign="top"><strong>Very low quality</strong> &mdash; The Canadian Task Force on Preventive Health Care (CTFPHC) is very uncertain about the estimate.</td>
                    </tr>
                </tbody>
            </table>
            <p><span style="text-decoration: underline;"><strong>Grading of Recommendations</strong></span></p>
            <ul style="list-style-type: disc;">
                <li><strong>Strong recommendations</strong> are those for which the Canadian Task Force on Preventive Health Care (CTFPHC) is confident that the desirable effects of an intervention outweigh its undesirable effects (strong recommendation for an intervention) or that the undesirable effects of an intervention outweigh its desirable effects (strong recommendation against an intervention). A strong recommendation implies that most people will be best served by the recommended course of action. </li>
                <li><strong>Weak recommendations</strong> are those for which the desirable effects probably outweigh the undesirable effects (weak recommendation for an intervention) or undesirable effects probably outweigh the desirable effects (weak recommendation against an intervention) but appreciable uncertainty exists. A weak recommendation implies that most people would want the recommended course of action, but many would not. For clinicians, this means they must recognize that different choices will be appropriate for each individual, and they must help each person arrive at a management decision consistent with his or her own values and preferences. Policy-making will require substantial debate and involvement of various stakeholders. Weak recommendations result when the balance between desirable and undesirable effects is small, the quality of evidence is lower, and there is more variability in the values and preferences of patients. </li>
            </ul>
            </td>
        </tr>
        <tr>
            <th width="10%" class="Center" valign="top">USPSTF<br />
            (2014)</th>
            <td valign="top" style="width: 90%;">
            <p><strong>What the U.S. Preventive Services Task Force (USPSTF) Grades Mean and Suggestions for Practice</strong></p>
            <table role="presentation" border="1" cellspacing="1" cellpadding="3" summary="Table: What the U.S. Preventive Services Task Force (USPSTF) Grades Mean and Suggestions for Practice">
                <thead>
                    <tr>
                        <th class="Center" valign="top" scope="col">Grade</th>
                        <th class="Center" valign="top" scope="col">Grade Definitions</th>
                        <th class="Center" valign="top" scope="col">Suggestions for Practice</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="Center" valign="top" scope="row">A</td>
                        <td valign="top">The USPSTF recommends the service. There is high certainty that the net benefit is substantial.</td>
                        <td valign="top">Offer/provide this service.</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">B</td>
                        <td valign="top">The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.</td>
                        <td valign="top">Offer/provide this service.</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">C</td>
                        <td valign="top">The USPSTF recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.</td>
                        <td valign="top">Offer/provide this service for selected patients depending on individual circumstances.</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">D</td>
                        <td valign="top">The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.</td>
                        <td valign="top">Discourage the use of this service.</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">I<br />
                        Statement</td>
                        <td valign="top">The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be measured.</td>
                        <td valign="top">Read the "Clinical Considerations" section of the USPSTF Recommendation Statement (see the "Major Recommendations" field). If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.</td>
                    </tr>
                </tbody>
            </table>
            <p><strong>USPSTF Levels of Certainty Regarding Net Benefit</strong></p>
            <p><strong>Definition</strong>: The USPSTF defines <em>certainty</em> as "likelihood that the USPSTF assessment of the net benefit of a preventive service is correct." The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature of the overall evidence available to assess the net benefit of a preventive service.</p>
            <table role="presentation" border="1" cellspacing="1" cellpadding="3" summary="Table: USPSTF Levels of Certainty Regarding Net Benefit">
                <thead>
                    <tr>
                        <th class="Center" valign="top" scope="col">Level of Certainty</th>
                        <th class="Center" valign="top" scope="col">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="Center" valign="top" scope="row">High</td>
                        <td valign="top">The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">Moderate</td>
                        <td valign="top">The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by factors such as:
                        <ul style="list-style-type: disc;">
                            <li>The number, size, or quality of individual studies </li>
                            <li>Inconsistency of findings across individual studies </li>
                            <li>Limited generalizability of findings to routine primary care practice </li>
                            <li>Lack of coherence in the chain of evidence </li>
                        </ul>
                        As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion. </td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" scope="row">Low</td>
                        <td valign="top">The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of:
                        <ul style="list-style-type: disc;">
                            <li>The limited number or size of studies </li>
                            <li>Important flaws in study design or methods </li>
                            <li>Inconsistency of findings across individual studies </li>
                            <li>Gaps in the chain of evidence </li>
                            <li>Findings not generalizable to routine primary care practice </li>
                            <li>A lack of information on important health outcomes </li>
                        </ul>
                        More information may allow an estimation of effects on health outcomes. </td>
                    </tr>
                </tbody>
            </table>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="507" role="tab" aria-expanded="true" aria-controls="syn507"><a href="#">Methodology</a></h2>
			<div class="accordion-panel is-active" id="syn507" role="tabpanel" aria-labelledby="507" ><table width="100%" border="1" cellspacing="1" cellpadding="8" summary="This table presents the comparison of methodology for each guideline in the synthesis.">
    <tbody>
        <tr>
            <th class="SynthesesCellGreen" valign="top" colspan="2" scope="col"><em>Click on the links below for details of guideline development methodology</em> </th>
        </tr>
        <tr>
            <td class="Center" valign="top">
            <p><strong><a href="/summaries/summary/49951?#405" title="Guideline #10869" target="_blank">CTFPHC</a><br />
            (2016)</strong></p>
            </td>
            <td class="Center" valign="top">
            <p><strong><a href="/summaries/summary/48059?#405" title="Guideline #10364" target="_blank">USPSTF</a><br />
            (2014)</strong></p>
            </td>
        </tr>
        <tr>
            <td valign="top" colspan="2">
            <p>The CTFPHC and USPSTF guidelines were developed from systematic reviews of the evidence and original meta-analyses conducted by the McMaster Evidence Review and Synthesis Centre (ERSC) Team and the Kaiser Permanente Research Affiliates Evidence-based Practice Center (EPC), respectively. Both systematic reviews provide relevant details of the literature search and selection process, including the electronic databases that were searched, time period of the search, search terms used, and the inclusion and exclusion criteria applied. CTFPHC used a modified search strategy based on the literature search conducted by the USPSTF for its guideline. To assess the quality and strength of the selected evidence, the guideline developers weighted it according to a rating scheme and provide the scheme. Both CTFPHC and the USPSTF formulated the guideline recommendations using an expert consensus process, and rated the strength of the individual recommendations according to a scheme. To validate the guidelines, both CTFPHC and the USPSTF sought internal and external peer review and compared their recommendations to those in guidelines developed by other groups.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="509" role="tab" aria-expanded="true" aria-controls="syn509"><a href="#">Benefits and Harms</a></h2>
			<div class="accordion-panel is-active" id="syn509" role="tabpanel" aria-labelledby="509" ><p><a name="source"></a></p>
<h3>Benefits</h3>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="provides a comparison of recommendations considered by each group.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">CTFPHC<br />
            (2016)</th>
            <td valign="top" style="width: 90%;">
            <p><strong><span style="text-decoration: underline;">Benefits of Screening and Treatment</span></strong></p>
            <p>The evidence review identified no trials that examined the effectiveness of screening for cognitive impairment on patient outcomes (function, quality of life, health care utilization and safety), family and caregiver outcomes (quality of life, caregiver burden) or societal outcomes (safety) (see Appendix 1 in the online appendices [see the "Availability of Companion Documents" field in the NGC summary]). The review identified 12 RCTs that examined the effects of treatment interventions for MCI on cognition, function, behaviour and global status. No studies were identified that examined the effect of treatment interventions on mortality.</p>
            <p>For all results on the outcome of cognition reported, it is important to note that negative and positive effects are outcome-measure dependent. For MMSE, increases in score (positive values) indicate an improvement; however, for Alzheimer's Disease Assessment Scale (ADAS-cog), decreases in score (negative values) indicate an improvement. See the original guideline document for specific interventions, such as cholinesterase inhibitors, dietary supplements and vitamins, and nonpharmacologic interventions.</p>
            </td>
        </tr>
        <tr>
            <th width="10%" class="Center" valign="top">USPSTF<br />
            (2014)</th>
            <td valign="top" style="width: 90%;">
            <p><strong>Benefits of Detection and Early Intervention</strong></p>
            <p>The USPSTF found inadequate direct evidence on the benefits of screening for cognitive impairment. Evidence shows that several drug therapies and nonpharmacologic interventions have a small effect on cognitive function measures in the short term for patients with mild to moderate dementia, but the magnitude of the clinically relevant benefit is uncertain. The USPSTF found adequate evidence that interventions targeted to caregivers have a small effect on measures of caregiver burden and depression, but the magnitude of the clinically relevant benefit is uncertain. The USPSTF found no published evidence on the effect of screening on decision making or planning by patients, clinicians, or caregivers.</p>
            </td>
        </tr>
    </tbody>
</table>
<h3>Harms</h3>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="provides a comparison of recommendations considered by each group.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">CTFPHC<br />
            (2016)</th>
            <td valign="top" style="width: 90%;">
            <p><strong><span style="text-decoration: underline;">Harms</span></strong></p>
            <p>No studies were identified by the Evidence Review and Synthesis Centre on the harms of screening (shown in Appendix 1 in the online appendices [see the "Availability of Companion Documents" field in the NGC summary]).</p>
            <p>The systematic review for treatment also used RCTs to examine harms associated with the treatment of MCI and found no evidence that pharmacologic treatments were associated with an increased number of serious adverse events or psychosocial harms (e.g., depression and lack of independence) compared with controls. Seven RCTs that examined the effects of dietary supplements or vitamins or the effects of nonpharmacologic treatments reported that no serious adverse events occurred.</p>
            </td>
        </tr>
        <tr>
            <th class="Center" valign="top">USPSTF<br />
            (2014)</th>
            <td valign="top">
            <p><strong>Harms of Detection and Early Intervention or Treatment</strong></p>
            <p>The USPSTF found inadequate evidence on the harms of screening for cognitive impairment and of nonpharmacologic interventions. It found adequate evidence that acetylcholinesterase inhibitors are associated with adverse effects, some of which are serious, including central nervous system disturbances and arrhythmia. Gastrointestinal symptoms are also common.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="511" role="tab" aria-expanded="true" aria-controls="syn511"><a href="#">Abbreviations</a></h2>
			<div class="accordion-panel is-active" id="syn511" role="tabpanel" aria-labelledby="511" ><p>ADAS-cog, Alzheimer's Disease Assessment Scale</p>
<p>CTFPHC, Canadian Task Force on Preventive Health Care</p>
<p>EPC, Evidence-based Practice Center</p>
<p>ERSC, Evidence Review and Synthesis Centre</p>
<p>MCI, mild cognitive impairment</p>
<p>MMSE, Mini-Mental State Examination</p>
<p>RCT, randomized, controlled trial</p>
<p>USPSTF, U.S. Preventive Services Task Force</p></div>
			<h2 class="accordion-title is-active" id="512" role="tab" aria-expanded="true" aria-controls="syn512"><a href="#">Status</a></h2>
			<div class="accordion-panel is-active" id="syn512" role="tabpanel" aria-labelledby="512" ><p>This synthesis was prepared by ECRI Institute on February 21, 2017. The information was verified by USPSTF on March 16, 2017.</p></div>
	</div><!-- accordion-container -->

<!-- ASIDE -->


		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				
	<!-- About NGC -->
	<div class="info-block">
			<h3 class="info prefix-icon large-icon">About NGC Guideline Syntheses</h3>
			<p>Syntheses are systematic comparisons of selected guidelines that address similar topics. For definitions of synthesis attributes, see the 
                <a href="/syntheses/template">Guideline Synthesis Template</a>.    
            </p>
	</div><!-- /info-block -->
	<hr>

	<!-- New on NGC -->
	<div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
		<ul class="subscribe-links">
            <li><a href="/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/rssFiles/ngc_newthisweek.xml" class="rss icon-feed"><span class="subscribe-links-label">RSS Feed</span></a></li>
		</ul>
	</div><!-- /.subscribable -->

	<!-- New this Week -->
	<a href="/new-this-week" class="block-link">
		<h4>New this Week</h4>
		<p>View more and sign up for our Newsletter</p>
	</a>

	<!-- Adobe Reader -->
	<p><a href="#" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	


</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source
					  		type="image/svg+xml"
					    	srcset="/UI/images/logo_NGC_footer.svg">
					  	<img 
						    src="/UI/images/logo_NGC_footer.png"
						    alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/">Home</a></li>
		                <li><a href="/new-this-week/index">New This Week</a></li>
						<li><a href="/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/expert">Expert Commentaries</a></li>
		                <li><a href="/matrix">Matrix Tool</a></li>
						<li><a href="/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/contact-us">Contact Us</a></li>
						<li><a href="/rss">RSS</a></li>
					    <li><a href="/site-map">Site Map</a></li>
                        <li><a href="/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://www.qualitymeasures.ahrq.gov" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/UI/images/logo_footerlink_nqmc.svg">
									<img src="/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/UI/images/logo_footerlink_hmis.svg">
								    <img src="/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="http://www.facebook.com" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="http://www.twitter.com" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="http://www.linkedin.com" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="http://www.youtube.com" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
